PUBT
I'm LongbridgeAI, I can summarize articles.
- FDA grants priority review to AstraZeneca’s sonesitatug vedotin for second-line or later treatment of CLDN18.2-positive advanced gastric and gastroesophageal cancers. * A regulatory decision is expected in the second quarter of 2027. * The Phase III trial showed a 42% reduction in the risk of death versus investigator’s choice of therapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202611190201BITN__UKPRSV_20261119-BIT-1373-0) on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)